Pharmaco-EEG study of 6-azamianserin (ORG 3770): dissociation of EEG and pharmacologic predictors of antidepressant activity.
The effects of a single oral dose of 6-azamianserin (2 mg) were compared to those of mianserin (6 mg), flurazepam (10 mg), and placebo in 11 healthy male volunteers, in a crossover design. Quantitative EEG, heart rate, blood pressure, task performance, and subjective state were measured. EEG and behavioral measures distinguished the substances from placebo. 6-Azamianserin was similar to mianserin in type and duration of effects. In a separate study in 12 volunteers, 0.5 and 1.0 mg of the (+) and (-) enantiomers of 6-azamianserin elicited dose-related EEG and behavioral effects, distinguishable from placebo. These effects were similar to those elicited by racemic 6-azamianserin and mianserin. Clinical trials of 6-azamianserin in depressed patients, particularly the elderly and those with cardiovascular disease, are warranted. Dosages selected should be one-third those of mianserin. The stereospecific properties of the enantiomers in preclinical tests predict that any clinical 'antidepressant' activity will reside in the (+) isomer only, while the pharmaco-EEG trials predict that both enantiomers will be clinically 'antidepressant'. Clinical testing of the isomers, particularly the (-) isomer, is indicated as a test of the predictive value of pharmacologic and pharmaco-EEG models of clinical antidepressant activity.